Reuters

30 May 2026, 15:20 UTC · 1h ago

Mineralys' pill cuts blood pressure in kidney disease patients

Source · https://www.reuters.com/business/healthcare-pharmaceuticals/mineralys-pill-cuts-blood-pressure-kidney-disease-patients-2026-05-30/

Read source

Mineralys' pill cuts blood pressure in kidney disease patients

Search tags

Story key points

1 claims · impact-rated

What matters in this story

1
Mineralys Therapeutics' experimental drug significantly reduced blood pressure in patients with chronic kidney disease. — Positive clinical data for a primary endpoint in a high-need patient population typically acts as a strong catalyst for biotechnology stock appreciation.
+0.80

Ticker attribution

Model heads

Sentiment in this article

No ticker sentiment head found.

Relationships in this article

No ticker relationship head found.

Impact vectors

3 dimensions · 9 clusters

Analytical profile by cluster

Market Behaviour+0.800

6 related stories

PRNewsWire
18h ago
IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit
- biotech
- clinical trials
- pharmaceuticals
Read

News Impact Screener — Catch market-moving news before the crowd

Mineralys' pill cuts blood pressure in kidney disease patients

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Mineralys' pill cuts blood pressure in kidney disease patients

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Top impact dimensions

Most positively impacted

Most negatively impacted

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Mailbag: A Follow-Up on Pfizer & Other Questions

Mineralys' pill cuts blood pressure in kidney disease patients

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Next reads from the same story arc

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Mineralys' pill cuts blood pressure in kidney disease patients

What matters in this story

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Next reads from the same story arc

IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit

Top impact dimensions

Most positively impacted

Most negatively impacted

Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026

GOSS DEADLINE MONDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Gossamer Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 1 Deadline in Securities Class Action - GOSS

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Dianthus Therapeutics: A Financed Autoimmune Platform With More Than One Way To Win

Mailbag: A Follow-Up on Pfizer & Other Questions